ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2013
Expression of the RNase III enzyme DROSHA is reduced during progression of human cutaneous melanoma.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- miRNAs and arsenic-induced carcinogenesis.Advances in pharmacology (San Diego, Calif.) · 2023Review
- Sequencing of Argonaute-bound microRNA/mRNA hybrids reveals regulation of the unfolded protein response by microRNA-320a.PLoS genetics · 2021Article
- Evaluation of the clinical significance of RNase III enzyme DROSHA in pediatrics acute lymphocytic leukemia.Molecular biology reports · 2021Article
- Review
- Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases.Frontiers in pharmacology · 2019Review
- Dicer cleaves 5'-extended microRNA precursors originating from RNA polymerase II transcription start sites.Nucleic acids research · 2018Article
- Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.International journal of molecular sciences · 2018Article
- Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in gastric cancer.Cell death & disease · 2017Article
- Cytoplasmic Drosha activity generated by alternative splicing.Nucleic acids research · 2016Article
- Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.Molecular cancer research : MCR · 2016Article
- Cytoplasmic Drosha Is Aberrant in Precancerous Lesions of Gastric Carcinoma and Its Loss Predicts Worse Outcome for Gastric Cancer Patients.Digestive diseases and sciences · 2016Article
- Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.Journal of leukocyte biology · 2015Article
- Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.Cellular oncology (Dordrecht, Netherlands) · 2015Article
- MicroRNA biogenesis pathways in cancer.Nature reviews. Cancer · 2015Review
- Reply to comment on: Strong reduction of AGO2 expression in melanoma and cellular consequences.British journal of cancer · 2014Article
- An essential microRNA maturing microprocessor complex component DGCR8 is up-regulated in colorectal carcinomas.Clinical and experimental medicine · 2014Article
- miRNA biogenesis: biological impact in the development of cancer.Cancer biology & therapy · 2014Review
- Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyArticle
- Dysregulation of microRNA biogenesis machinery in cancer.Critical reviews in biochemistry and molecular biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Aberrant expression of microRNAs (miRNAs) and their biogenesis factors has been frequently observed in different types of cancer. We recently reported that expression of DICER1 is reduced in metastatic melanoma. Nevertheless, so far very little is known about the expression pattern of other miRNA biogenesis factors in this type of malignancy. Here, we investigated the expression pattern of DROSHA in a large set of melanocytic lesions (n=409) by tissue microarray and immunohistochemistry. We found that nuclear expression of DROSHA is markedly reduced in the early stages of melanoma progression (P=0.0001) and is inversely correlated with melanoma thickness (P=0.0001), AJCC stages (P=0.0001), and ulceration status (P=0.002). We also confirmed the reduced expression of nuclear DROSHA by a second specific antibody raised against a different region of the DROSHA protein. In addition, we observed that the reduced nuclear expression of DROSHA during melanoma progression is accompanied by an increased cytoplasmic expression of this protein (P=0.0001). Finally, we found that expression pattern of DROSHA varies from that of DICER1 and concomitant loss of expression of both DICER1 and DROSHA confers the worse outcome for melanoma patients. Our results demonstrate a reduced nuclear expression of DROSHA, which further highlights a perturbed miRNA biogenesis pathway in melanoma. In addition, the aberrant subcellular localization of DROSHA indicates possible deregulation in the mechanisms responsible for its proper localization in the nucleus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.